• 1. An antioxidant self-healing hydrogel for 3D cell cultures?
  Lei Yang,Yuan Zeng,Haibo Wu,Chunwu Zhou,Lei Tao J. Mater. Chem. B, 2020,8, 1383-1388
• 2. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 3. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 4. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 5. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551

Recent Advances in the Application of Ethyl 2-(picolinamido)acetate (CAS: 39484-31-6) in Chemical Biology and Pharmaceutical Research

Ethyl 2-(picolinamido)acetate (CAS: 39484-31-6) has emerged as a compound of significant interest in chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. Recent studies have highlighted its role as a key intermediate in the synthesis of bioactive molecules, particularly in the design of enzyme inhibitors and receptor modulators. This research brief provides an overview of the latest findings related to this compound, focusing on its synthetic utility, biological activities, and potential therapeutic applications.

A recent study published in the Journal of Medicinal Chemistry (2023) demonstrated the use of Ethyl 2-(picolinamido)acetate as a precursor in the synthesis of novel histone deacetylase (HDAC) inhibitors. The researchers utilized this compound to develop a series of hydroxamic acid derivatives, which exhibited potent inhibitory activity against HDAC isoforms implicated in cancer progression. The study reported IC50 values in the nanomolar range for several derivatives, suggesting promising therapeutic potential for oncology applications.

In the field of antimicrobial research, Ethyl 2-(picolinamido)acetate has been employed as a building block for the development of new antibacterial agents. A 2024 study in Bioorganic & Medicinal Chemistry Letters described its incorporation into novel quinolone hybrids, which showed enhanced activity against drug-resistant strains of Staphylococcus aureus. The structural flexibility of this compound allowed for optimal positioning of pharmacophores, leading to improved target binding and reduced susceptibility to bacterial efflux mechanisms.

From a synthetic chemistry perspective, recent advances have focused on optimizing the production and purification of Ethyl 2-(picolinamido)acetate. A 2023 patent application (WO2023187654) disclosed an improved synthetic route with higher yields and reduced environmental impact. The new method employs green chemistry principles, including water-based workup procedures and catalytic rather than stoichiometric reagents, addressing growing concerns about sustainable pharmaceutical manufacturing.

Emerging applications in neurological research have also been reported. A preclinical study published in ACS Chemical Neuroscience (2024) investigated derivatives of Ethyl 2-(picolinamido)acetate as potential neuroprotective agents. The compounds demonstrated ability to cross the blood-brain barrier and showed promising results in models of oxidative stress-induced neuronal damage, suggesting possible utility in neurodegenerative disease treatment.

In conclusion, Ethyl 2-(picolinamido)acetate (39484-31-6) continues to be a valuable scaffold in medicinal chemistry, with recent research expanding its applications across multiple therapeutic areas. The compound's structural features enable diverse modifications, making it particularly useful for structure-activity relationship studies. Future research directions may include further exploration of its pharmacokinetic properties and the development of more targeted derivatives for specific disease indications.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)